JP7590982B2 - Ｍａｇｅ ａ４ ｔ細胞受容体 - Google Patents

Ｍａｇｅ ａ４ ｔ細胞受容体 Download PDF

Info

Publication number
JP7590982B2
JP7590982B2 JP2021560302A JP2021560302A JP7590982B2 JP 7590982 B2 JP7590982 B2 JP 7590982B2 JP 2021560302 A JP2021560302 A JP 2021560302A JP 2021560302 A JP2021560302 A JP 2021560302A JP 7590982 B2 JP7590982 B2 JP 7590982B2
Authority
JP
Japan
Prior art keywords
tcr
seq
acid sequence
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527635A (ja
JP2022527635A5 (enExample
Inventor
クリスチャン エリンガー
ダニエル ゾンマーマイヤー
パーソンズ ジェフリー ブラックバーン
ジャスディ－プ マン
Original Assignee
メディジーン イミュノセラピーズ ゲーエムベーハー
２セブンティ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディジーン イミュノセラピーズ ゲーエムベーハー, ２セブンティ バイオ インコーポレイテッド filed Critical メディジーン イミュノセラピーズ ゲーエムベーハー
Publication of JP2022527635A publication Critical patent/JP2022527635A/ja
Publication of JP2022527635A5 publication Critical patent/JP2022527635A5/ja
Priority to JP2024199432A priority Critical patent/JP7877420B2/ja
Application granted granted Critical
Publication of JP7590982B2 publication Critical patent/JP7590982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021560302A 2019-03-27 2020-03-27 Ｍａｇｅ ａ４ ｔ細胞受容体 Active JP7590982B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024199432A JP7877420B2 (ja) 2019-03-27 2024-11-15 Ｍａｇｅ ａ４ ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19165387.2 2019-03-27
EP19165387.2A EP3714941A1 (en) 2019-03-27 2019-03-27 Mage-a4 tcrs
PCT/EP2020/058779 WO2020193767A1 (en) 2019-03-27 2020-03-27 Mage a4 t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199432A Division JP7877420B2 (ja) 2019-03-27 2024-11-15 Ｍａｇｅ ａ４ ｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2022527635A JP2022527635A (ja) 2022-06-02
JP2022527635A5 JP2022527635A5 (enExample) 2023-04-03
JP7590982B2 true JP7590982B2 (ja) 2024-11-27

Family

ID=66000958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021560302A Active JP7590982B2 (ja) 2019-03-27 2020-03-27 Ｍａｇｅ ａ４ ｔ細胞受容体
JP2024199432A Active JP7877420B2 (ja) 2019-03-27 2024-11-15 Ｍａｇｅ ａ４ ｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024199432A Active JP7877420B2 (ja) 2019-03-27 2024-11-15 Ｍａｇｅ ａ４ ｔ細胞受容体

Country Status (26)

Country Link
US (2) US12344654B2 (enExample)
EP (3) EP3714941A1 (enExample)
JP (2) JP7590982B2 (enExample)
KR (2) KR102957751B1 (enExample)
CN (2) CN114126716B (enExample)
AU (1) AU2020249598A1 (enExample)
BR (1) BR112021019066A2 (enExample)
CA (1) CA3134076A1 (enExample)
CL (1) CL2021002491A1 (enExample)
CO (1) CO2021012587A2 (enExample)
DK (1) DK3946621T3 (enExample)
EA (1) EA202192327A1 (enExample)
ES (1) ES3037919T3 (enExample)
FI (1) FI3946621T3 (enExample)
HR (1) HRP20250993T1 (enExample)
HU (1) HUE073008T2 (enExample)
IL (1) IL286569A (enExample)
LT (1) LT3946621T (enExample)
MX (1) MX2021011613A (enExample)
PL (1) PL3946621T3 (enExample)
PT (1) PT3946621T (enExample)
RS (1) RS67109B1 (enExample)
SG (1) SG11202110171QA (enExample)
SI (1) SI3946621T1 (enExample)
SM (1) SMT202500298T1 (enExample)
WO (1) WO2020193767A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11654158B2 (en) 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
MA55911A (fr) * 2019-05-08 2022-03-16 2Seventy Bio Inc Lymphocytes t génétiquement modifiés
WO2021195503A1 (en) * 2020-03-27 2021-09-30 2Seventy Bio, Inc. T cell receptors
CN111647069B (zh) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 一种改进的tcr及其应用
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) * 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
CN115975003B (zh) * 2021-03-09 2024-01-26 科士华(南京)生物技术有限公司 Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
CA3226947A1 (en) * 2021-08-03 2023-02-09 Muhammad YASSIN Engineered tcr complex and methods of using same
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
CN119569851A (zh) * 2023-09-05 2025-03-07 香雪生命科学技术（广东）有限公司 针对magea4的高亲和力tcr
WO2025219541A1 (en) * 2024-04-19 2025-10-23 Medigene Immunotherapies Gmbh Constant uni-tabs
EP4635976A1 (en) * 2024-04-19 2025-10-22 Medigene Immunotherapies GmbH Constant uni-tabs
CN122344246A (zh) * 2025-01-02 2026-07-07 中国科学院微生物研究所 Mage-a4特异性t细胞受体筛选及抗肿瘤用途
CN121342955B (zh) * 2025-12-18 2026-03-06 中山大学孙逸仙纪念医院 T细胞受体、融合蛋白、慢病毒、tcr-t细胞及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017174824A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
WO2017175006A1 (en) 2016-04-08 2017-10-12 Immunocore Limited T cell receptors
WO2019036688A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
EP2006376A1 (en) 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
US9879065B2 (en) 2012-09-14 2018-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing MHC class II-restricted MAGE-A3
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP2944652A1 (en) 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
US11654158B2 (en) 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
MA55911A (fr) 2019-05-08 2022-03-16 2Seventy Bio Inc Lymphocytes t génétiquement modifiés

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017174824A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
WO2017175006A1 (en) 2016-04-08 2017-10-12 Immunocore Limited T cell receptors
WO2019036688A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Also Published As

Publication number Publication date
EP3946621B1 (en) 2025-05-21
FI3946621T3 (fi) 2025-07-31
CN114126716B (zh) 2024-05-24
SMT202500298T1 (it) 2025-09-12
EP4631516A3 (en) 2026-08-12
KR20210150440A (ko) 2021-12-10
SI3946621T1 (sl) 2025-10-30
LT3946621T (lt) 2025-08-25
WO2020193767A1 (en) 2020-10-01
HRP20250993T1 (hr) 2025-10-24
ES3037919T3 (en) 2025-10-08
US20250346648A1 (en) 2025-11-13
JP2022527635A (ja) 2022-06-02
CL2021002491A1 (es) 2022-06-10
EP3714941A1 (en) 2020-09-30
US20230159612A1 (en) 2023-05-25
CO2021012587A2 (es) 2022-02-28
BR112021019066A2 (pt) 2021-11-30
DK3946621T3 (da) 2025-08-18
MX2021011613A (es) 2021-12-15
US12344654B2 (en) 2025-07-01
SG11202110171QA (en) 2021-10-28
RS67109B1 (sr) 2025-09-30
PT3946621T (pt) 2025-08-14
CN114126716A (zh) 2022-03-01
CN118580335A (zh) 2024-09-03
KR20260061466A (ko) 2026-05-06
IL286569A (en) 2021-12-01
EP3946621A1 (en) 2022-02-09
KR102957751B1 (ko) 2026-04-24
CA3134076A1 (en) 2020-10-01
JP2025024103A (ja) 2025-02-19
EP4631516A2 (en) 2025-10-15
AU2020249598A1 (en) 2021-10-28
JP7877420B2 (ja) 2026-06-22
PL3946621T3 (pl) 2025-11-03
EA202192327A1 (ru) 2022-01-19
HUE073008T2 (hu) 2025-12-28

Similar Documents

Publication Publication Date Title
US20250346648A1 (en) Mage a4 t cell receptors
US12103957B2 (en) Nyeso tcr
CN113840834B (zh) Magea1特异性t细胞受体及其用途
CA3146227A1 (en) Magea10 specific t cell receptors and their use
JP2023542208A (ja) Ｍａｇｅ－ａ３特異的ｔ細胞受容体およびその使用
CA3090917C (en) Nyeso tcr
EA052535B1 (ru) T-клеточные рецепторы, специфичные к mage-a4
EA048001B1 (ru) T-клеточные рецепторы, специфичные к mage-a4
HK40067706B (en) Mage a4 t cell receptors
HK40067706A (en) Mage a4 t cell receptors
HK40015259B (en) Nyeso tcr
HK40015259A (en) Nyeso tcr
EA051766B1 (ru) Специфические для magea10 t-клеточные рецепторы и их применение
HK40042687A (en) Nyeso t cell receptor (tcr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241115

R150 Certificate of patent or registration of utility model

Ref document number: 7590982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350